Prognostic value of PCT, copeptin, MR-proADM, MR-proANP and CT-proET-1 for severe acute dyspnea in the emergency department: the BIODINER study

References

• Bossuyt PM, Reitsma JB, Bruns DE, et al. (2007). Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Vet Clin Pathol 36:8–12.
   Web of Science ®Google Scholar
• Burri E, Potocki M, Drexler B, et al. (2011). Value of arterial blood gas analysis in patients with acute dyspnea: an observational study. Crit Care 15:R145.
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Morgenthaler NG, Stolz D, et al. (2006). Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 10:R96.
   PubMed Web of Science ®Google Scholar
• Cinar O, Cevik E, Acar A, et al. (2012). Evaluation of mid-regional pro-atrial natriuretic peptide, procalcitonin, and mid-regional pro-adrenomedullin for the diagnosis and risk stratification of ED patients with dyspnea. Am J Emerg Med 30:1915–20.
   PubMed Web of Science ®Google Scholar
• Courtais C, Kuster N, Dupuy AM, et al. (2012). Proadrenomedullin, a useful tool for risk stratification in high pneumonia severity index score community acquired pneumonia. Am J Emerg Med 31:215–21.
   PubMed Web of Science ®Google Scholar
• de Kruif MD, Limper M, Gerritsen H, et al. (2010). Additional value of procalcitonin for diagnosis of infection in patients with fever at the emergency department. Crit Care Med 38:457–63.
   PubMed Web of Science ®Google Scholar
• Guignant C, Voirin N, Venet F, et al. (2009). Assessment of pro-vasopressin and pro-adrenomedullin as predictors of 28-day mortality in septic shock patients. Intensive Care Med 35:1859–67.
   PubMed Web of Science ®Google Scholar
• Hausfater P, Hurtado M, Pease S, et al. (2008). Is procalcitonin a marker of critical illness in heatstroke? Intensive Care Med 34:1377–83.
   PubMed Web of Science ®Google Scholar
• Hausfater P, Juillien G, Madonna-Py B, et al. (2007). Serum procalcitonin measurement as diagnostic and prognostic marker in febrile adult patients presenting to the emergency department. Crit Care 11:R60.
   PubMed Web of Science ®Google Scholar
• Huang DT, Weissfeld LA, Kellum JA, et al. (2008). Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 52:48–58.e2.
   PubMed Web of Science ®Google Scholar
• Khan SQ, O’brien RJ, Struck J, et al. (2007). Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Col Cardiol 49:1525–32.
   PubMed Web of Science ®Google Scholar
• Krüger S, Ewig S, Giersdorf S, et al. (2010a). Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German competence network, CAPNETZ. Am J Respir Crit Care Med 182:1426–34.
   PubMed Web of Science ®Google Scholar
• Krüger S, Ewig S, Kunde J, et al. (2010b). Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in community-acquired pneumonia: results from the German competence network CAPNETZ. Thorax 65:208–14.
   PubMed Web of Science ®Google Scholar
• Maisel A, Mueller C, Nowak R, et al. (2010). Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 55:2062–76.
   PubMed Web of Science ®Google Scholar
• Maisel A, Neath SX, Landsberg J, et al. (2012). Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. Eur J Heart Fail 14:278–86.
   PubMed Web of Science ®Google Scholar
• Melander O, Newton-Cheh C, Almgren P, et al. (2009). Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 302:49–57.
   PubMed Web of Science ®Google Scholar
• Mockel M, Searle J, Muller R, et al. (2013). Chief complaints in medical emergencies: do they relate to underlying disease and outcome? The Charité Emergency Medicine Study (CHARITEM). Eur J Emerg Med 20:103–8.
   PubMed Web of Science ®Google Scholar
• Neuhold S, Huelsmann M, Strunk G, et al. (2010). Prognostic value of emerging neurohormones in chronic heart failure during optimization of heart failure-specific therapy. Clin Chem 56:121–6.
   PubMed Web of Science ®Google Scholar
• Peacock WF, Nowak R, Christenson R, et al. (2011). Short-term mortality risk in emergency department acute heart failure. Acad Emerg Med 18:947–58.
   PubMed Web of Science ®Google Scholar
• Potocki M, Breidthardt T, Reichlin T, et al. (2009). Midregional pro-adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study. Crit Care 13:R122.
   Web of Science ®Google Scholar
• Ray P, Birolleau S, Lefort Y, et al. (2006). Acute respiratory failure in the elderly: etiology, emergency diagnosis and prognosis. Crit Care 10:R82.
   PubMed Web of Science ®Google Scholar
• Shah RV, Truong QA, Gaggin HK, et al. (2012). Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J 33:2197–205.
   PubMed Web of Science ®Google Scholar
• Stolz D, Christ-Crain M, Morgenthaler NG, et al. (2008). Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. Chest 134:263–72.
   PubMed Web of Science ®Google Scholar
• Travaglino F, Russo V, De Berardinis B, et al. (2014). Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial. Am J Emerg Med 32:334–41.
   PubMed Web of Science ®Google Scholar
• von Haehling S, Jankowska EA, Morgenthaler NG, et al. (2007). Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol 50:1973–80.
   PubMed Web of Science ®Google Scholar